

RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage

Coutinho de Almeida, Rodrigo; Ramos, Yolande F.M.; Mahfouz, Ahmed; den Hollander, Wouter; Lakenberg, Nico; Houtman, Evelyn; van Hoolwerff, Marcella; Suchiman, H. Eka D.; Rodriguez-Ruiz, Alejandro; Slagboom, P. Eline

DOI

[10.1136/annrheumdis-2018-213882](https://doi.org/10.1136/annrheumdis-2018-213882)

Publication date

2018

Document Version

Final published version

Published in

Annals of the Rheumatic Diseases: an international peer-reviewed journal for health professionals and researchers in the rheumatic diseases

Citation (APA)

Coutinho de Almeida, R., Ramos, Y. F. M., Mahfouz, A., den Hollander, W., Lakenberg, N., Houtman, E., van Hoolwerff, M., Suchiman, H. E. D., Rodriguez-Ruiz, A., Slagboom, P. E., Mei, H., Kielbasa, S. M., Nelissen, R., Reinders, M., & Meulenbelt, I. (2018). RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage. *Annals of the Rheumatic Diseases: an international peer-reviewed journal for health professionals and researchers in the rheumatic diseases*, 1-8. Advance online publication. <https://doi.org/10.1136/annrheumdis-2018-213882>

Important note

To cite this publication, please use the final published version (if applicable). Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy

Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.



OPEN ACCESS

EXTENDED REPORT

RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage

Rodrigo Coutinho de Almeida,¹ Yolande F M Ramos,¹ Ahmed Mahfouz,^{2,3} Wouter den Hollander,¹ Nico Lakenberg,¹ Evelyn Houtman,¹ Marcella van Hoolwerff,¹ H Eka D Suchiman,¹ Alejandro Rodríguez Ruiz,¹ P Eline Slagboom,¹ Hailiang Mei,⁴ Szymon M Kiełbasa,^{1,4} Rob G H H Nelissen,⁵ Marcel Reinders,^{1,2} Ingrid Meulenbelt¹

Handling editor Professor Josef S Smolen

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2018-213882>).

For numbered affiliations see end of article.

Correspondence to

Dr Ingrid Meulenbelt, Department of Molecular Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; i.meulenbelt@lumc.nl

RCdA and YFMR contributed equally.

MR and IM are joint senior authors.

Received 6 June 2018
Revised 9 November 2018
Accepted 12 November 2018



© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Coutinho de Almeida R, Ramos YFM, Mahfouz A, et al. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2018-213882

ABSTRACT

Objective To uncover the microRNA (miRNA) interactome of the osteoarthritis (OA) pathophysiological process in the cartilage.

Methods We performed RNA sequencing in 130 samples (n=35 and n=30 pairs for messenger RNA (mRNA) and miRNA, respectively) on macroscopically preserved and lesioned OA cartilage from the same patient and performed differential expression (DE) analysis of miRNA and mRNAs. To build an OA-specific miRNA interactome, a prioritisation scheme was applied based on inverse Pearson's correlations and inverse DE of miRNAs and mRNAs. Subsequently, these were filtered by those present in predicted (TargetScan/microT-CDS) and/or experimentally validated (miRTarBase/TarBase) public databases. Pathway enrichment analysis was applied to elucidate OA-related pathways likely mediated by miRNA regulatory mechanisms.

Results We found 142 miRNAs and 2387 mRNAs to be differentially expressed between lesioned and preserved OA articular cartilage. After applying prioritisation towards likely miRNA-mRNA targets, a regulatory network of 62 miRNAs targeting 238 mRNAs was created. Subsequent pathway enrichment analysis of these mRNAs (or genes) elucidated that genes within the 'nervous system development' are likely mediated by miRNA regulatory mechanisms (familywise error=8.4×10⁻⁵). Herein *NTF3* encodes neurotrophin-3, which controls survival and differentiation of neurons and which is closely related to the nerve growth factor.

Conclusions By an integrated approach of miRNA and mRNA sequencing data of OA cartilage, an OA miRNA interactome and related pathways were elucidated. Our functional data demonstrated interacting levels at which miRNA affects expression of genes in the cartilage and exemplified the complexity of functionally validating a network of genes that may be targeted by multiple miRNAs.

INTRODUCTION

Osteoarthritis (OA) is an age-related, disabling joint disease characterised by progressive heterogeneous changes in articular cartilage and subchondral bone. OA is the most common arthritic disease causing serious restrictions in major daily life activities, yet without an effective treatment.¹ At the tissue level, it has been demonstrated that OA pathophysiology is marked by

Key messages**What is already known about this subject?**

- Dysfunctional microRNA-messenger RNA (miRNA-mRNA) interactions have been demonstrated to mark osteoarthritis (OA) pathophysiology.
- Targeting dysfunctional miRNA-mRNA interactions by miR mimics or antagomirs fulfil an important therapeutic promise.

What does this study add?

- A data integration framework to systematically identify miRNAs involved in OA pathophysiology.
- A first comprehensive miRNA interactome of OA pathophysiology.

How might this impact on clinical practice or future developments?

- The OA miRNA interactome provides a roadmap to pinpoint candidates for future miRNA-based therapies.

altered gene expression regulation.²⁻⁵ This may be triggered by dysfunctional adaptation processes of the bone and/or cartilage on inevitable challenges occurring during life, due to ageing,⁶ genetic make-up⁷ or mechanical (over)loading.⁸

A substantial number of mechanisms, commonly referred to as epigenetics, are known to dynamically regulate changes in gene expression, particularly relevant in postmitotic cells such as chondrocytes. Epigenetic variation includes DNA methylation at CpG sites, histone modifications, and expression of non-coding RNAs such as microRNAs (<22 base pairs; miRNA) and long non-coding RNAs (<200 base pairs).⁹⁻¹¹ miRNAs are known to play an important role in post-translational regulation of gene expression via antisense binding to messenger RNA (mRNA), whereas their dysfunction has been demonstrated to mark many complex diseases including OA.¹² Notably, targeting dysfunctional miRNA-mRNA interactions has emerged as an important therapeutic promise for preclinical development as exemplified by successfully applied miRNA mimics or anti-miRs in cancer.¹³




Figure 1 Data integration approach. Relative log normalised miRNA and mRNA expression matrices were concatenated. Next, differentially expressed miRNAs and genes were correlated and integrated according to the opposite direction of its FC. Further, miRNA–mRNA interactions from prediction tools and experimentally validated databases were integrated. Finally, target genes that followed these criteria were considered to build an OA miRNA–mRNA network. DE, differential expression; FC, fold change; miRNA, microRNA; mRNA, messenger RNA; OA, osteoarthritis.

With respect to OA, an increasing number of studies report on differential expression (DE) of miRNAs with ongoing OA pathophysiology.^{12–14} Nevertheless, the majority of these studies report on candidate miRNA and mRNA interactions, such as miR-140 with *ADAMTS5*, *MMP13* and *IGFBP5*.^{15–16} To explore the full miRNA interactome of OA pathophysiology and explore its full potential to dynamically regulate gene expression in articular cartilage, we performed genome-wide miRNA and mRNA sequencing in preserved and OA-affected articular cartilage samples. To prioritise the most likely genes sensitive to the OA process that are targeted by miRNAs, we applied a stepwise integrative approach to our partly overlapping miRNA and mRNA sequencing data sets of preserved and lesioned OA cartilage, integrated with data from publicly available databases such as those with target predictions as well as those with experimentally validated data.

METHODS

Sample description

Preserved and lesioned cartilage samples from the same donor were obtained from the Research in Articular osteoArthritis Cartilage (RAAK) study consisting of patients with OA who underwent joint replacement surgery due to an end-stage disease.⁴ In the current study, cartilage samples of 63 patients were included (online supplementary table-S1).

Small RNA and mRNA sequencing

Sequencing of high-quality miRNA and mRNA was performed on, respectively, the Illumina HiSeq 2500 and the HiSeq 2000/4000. A detailed description on alignment, mapping and normalisation is available in online supplementary materials.

DE analysis

DE analysis was performed on paired samples of both data sets, that is, 30 paired samples (14 knees and 16 hips) for miRNA and 35 paired samples for mRNA (28 knees and 7 hips; [figure 1](#)). miRNA DE analysis was also performed while stratifying for joint (14 paired knees and 16 paired hips) (online supplementary materials). Benjamini-Hochberg multiple testing corrected-p values with a significance cut-off of 0.05 are reported as false discovery rate (FDR).

Prioritisation of miRNA–mRNA targeting pairs

To generate an OA-specific miRNA interactome, we applied an integrated stepwise prioritisation approach ([figure 1](#)) to the identified set of DE miRNAs and mRNAs based on (1) significant negative Pearson's correlation ($|r| > 0.5$ and $p < 0.05$) between miRNA and mRNA levels (19 overlapping samples, 15 patients); (2) opposite direction of fold change (FC) of mRNA and miRNA between the paired samples; (3) miRNA–mRNA

target prediction from TargetScan¹⁷ and microT-CDS¹⁸; and (4) experimentally validated miRNA–mRNA target pairs downloaded from miRTarBase V.7.0¹⁹ and TarBase V.7.²⁰ Prioritised miRNA–mRNA target pairs were integrated into an miRNA–mRNA network based on their correlation and FCs (online supplementary materials).

Pathway enrichment

Pathway enrichment analysis was performed using the online tool DAVID²¹ while selecting Gene Ontology terms for biological processes (GOTERM_BP_DIRECT). Bonferroni multiple testing-corrected p values with a significance cut-off of 0.05 are reported as familywise error rate (FWER). Enrichment analyses of the DE genes with FC ≥ 2 were performed separately for further comparison. To specifically identify the miRNA regulated pathways in OA cartilage, enrichments of miRNA-target genes were performed using all significant DE genes (FDR<0.05) as background.

Functional validation

Primary chondrocytes isolated from three independent donors were transfected with antagomirs and miR mimics for miR-143-3 p, miR-329-3 p and miR-99a-3p using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) according to the manufacturer's protocol. Reverse transcriptase-quantitative PCR (RT-qPCR) was performed adjusting for the house-keeping genes *GAPDH* and *ARP* (for further details see online supplementary materials).

Data availability

FASTQ files are available on ArrayExpress E-MTAB-7313. The code to reproduce the analysis is available on <https://git.lumc.nl/rcoutinhodealmeida/miRNAmRNA>.

RESULTS

To identify the miRNA–mRNA regulatory landscape in OA cartilage, we performed a stepwise approach to integrate the miRNA (n=30 pairs) and mRNA (n=35 pairs) sequencing data sets of preserved and lesioned OA cartilage, samples containing n=19 overlapping samples (figure 1).

Differentially expressed miRNAs between lesioned and preserved OA cartilage

We found 142 DE miRNAs (FDR<0.05) between lesioned and preserved OA cartilage with absolute FCs ranging from 1.2 to 4.9 (figure 2A, online supplementary table-S2). The most significant DE miRNAs were miR-127-3 p (FC=0.5, FDR=1.1 $\times 10^{-6}$) and miR-451a (FC=2.3, FDR=1.2 $\times 10^{-6}$). As shown in figure 2A, the majority of DE miRNAs were upregulated in lesioned as compared with preserved OA cartilage (91 out of 142 miRNAs) with miR-206, recently reported in relation to OA,²² displaying the largest FC (FC=4.9, FDR=3.5 $\times 10^{-6}$). Conversely miR-504-5 p (FC=0.4, FDR=2 $\times 10^{-5}$) showed the largest fold decrease in lesioned OA cartilage (figure 2A, online supplementary table-S2). Next to miR-206, we found 40 other DE miRNAs that have consistently been associated with OA in functional follow-up studies, for example miR-140-5 p (FC=1.4, FDR=0.04), miR-143-3 p (FC=2.1, FDR=0.0001), miR-146a (FC=0.5, FDR=0.01) and miR-155-5 p (FC=1.8, FDR=0.005).^{16,23–25} Additionally, we identified 102 DE miRNAs not previously reported in OA, such as miR-95-3 p (FC=4.3, FDR=2.8 $\times 10^{-8}$), miR-3934-5 p (FC=1.9, FDR=1.8 $\times 10^{-6}$) and miR-99a-3p (FC=0.6, FDR=0.004). Moreover, several members of particular miRNA families are found to be differentially expressed, such as the miR-320 and let-7 family (online supplementary table-S2). DE expression was confirmed for four out of four miRNAs by applying RT-qPCR in independent paired preserved and lesioned OA cartilage samples (n=21): miR-127-3 p (FC=0.8, p=0.012), miR-451a (FC=2.3, p=0.024), miR-99a-3p (FC=0.8, p=0.0007) and miR143-3p (FC=1.8, p=0.07) (online supplementary figure-S1).

To explore whether we could detect joint site-specific miRNAs, stratified analyses for hip (n=16 pairs) and knee joints (n=15 pairs) were performed. Despite the relative equal number of samples, we found in the hip 117 (online supplementary table-S3) and in the knee 22 (online supplementary table-S4) significant DE miRNAs (FDR<0.05) between lesioned and preserved OA cartilage. Of these, 14 DE miRNAs were specific for hip cartilage (eg, miR-122-5 p: FC=5.14, FDR=6.6 $\times 10^{-5}$) and five for knee cartilage (online supplementary figure-S2). Notably miR-451a was the most significantly differentially expressed




Figure 2 Paired differential expression analyses between preserved and lesioned OA cartilage. (A) Volcano plot with the differentially expressed miRNAs. (B) Volcano plot with the differentially expressed genes. Blue circles represent downregulated miRNAs (A) or genes (B); circles are red when they are upregulated. Labelled are the top differentially expressed genes and miRNAs, as well as the known and novel discovered ones. FC, fold change; FDR, false discovery rate; miRNA, microRNA; OA, osteoarthritis.

Table 1 Pathways enrichment analysis of differentially expressed genes

Term	P values	FWER	Fold enrichment	Genes
Extracellular matrix organisation	1.82E-07	5.99E-05	5.20	MATN4, POSTN, VIT, COL9A1, LAMB3, TNFRSF11B, FBLN1, COL19A1, COL7A1, FOXF1, TNR, SERPINE1, TGFB1, LAMC2, VCAN, SPP1, FN1
Skeletal system development	3.07E-06	1.01E-03	5.69	BMP3, NOG, SOX11, POSTN, NPR3, FRZB, PAX1, TNFRSF11B, COL19A1, GDF10, VCAN, BMPR1B, BMP6
Cell adhesion	8.94E-05	2.93E-02	2.74	AMTN, POSTN, AJAP1, CDH6, TNFAIP6, LAMB3, WISP2, COL19A1, COL7A1, LSAMP, TNR, MSLN, TGFB1, DSC3, RELN, LAMC2, VCAN, CHL1, SPP1, FN1, AOC3
Positive regulation of gene expression	1.30E-04	4.25E-02	3.43	ODAM, WNT16, NOG, TESC, SOX11, IQGAP3, KIT, HMGA2, RIMS1, NTRK3, INHBA, FBLN1, ANK3, NGF, FN1

FWER, familywise error rate.

in the hip (FC=3.3, FDR=5.0×10⁻⁸) and total (FC=2.3, FDR=1.2×10⁻⁶) data set, yet not differentially expressed in the knee data set.

Genes differentially expressed between lesioned and preserved OA cartilage

We identified 2387 DE mRNAs or genes (FDR<0.05) between lesioned and preserved OA cartilage (figure 2B, online supplementary table-S5). Of these, 1188 genes were downregulated in lesioned compared with preserved OA cartilage, and 1199 upregulated (online supplementary table-S5). As shown in figure 2B, the most significantly downregulated gene was *CISH* (FC=0.5, FDR=4.7×10⁻¹⁸), encoding the cytokine inducible SH2 containing protein which is known as an important suppressor of cytokine signalling through the JAK-STAT5 pathway. The most significantly upregulated gene was *IL11* encoding interleukin-11, which also showed the largest FC in lesioned as compared with preserved OA cartilage (FC=22.7, FDR=1.5×10⁻²⁰). The genes *DCC* (FC=0.1, FDR=3.3×10⁻¹¹) and *CHRD2* (FC=0.1, FDR=7×10⁻⁹) showed the largest fold decrease in lesioned as compared with preserved OA cartilage (figure 2B, online supplementary table-S5). We found several previously reported OA-related genes, such as *WNT16* (FC=8.4, FDR=1.1×10⁻¹³) and *TNFRSF11B* (FC=3.0, FDR=7.1×10⁻¹²),²⁶ but also revealed new DE genes with OA, such as *P3H2* (FC=3.2, FDR=4.7×10⁻¹⁸) and *ISM2* (FC=5.2, FDR=4.7×10⁻¹⁸). As shown in table 1, enrichment analyses of the DE genes with FC≥2 (n=372) revealed significant enrichment (FWER <0.05) for pathways earlier reported in relation to OA pathophysiology (eg, ‘extracellular matrix organization’, ‘skeletal system development’, ‘cell adhesion’ and ‘positive regulation of gene expression’).

OA-specific miRNA interactome

To generate an OA-specific miRNA interactome of the most likely miRNA–mRNA target pairs, the integrated stepwise prioritisation approach outlined in figure 1 was applied using 19 samples for which we had both miRNA and mRNA sequencing data. In online supplementary table-S6 we provided the 331 prioritised miRNA–mRNA target pairs, including their target predictions and/or experimental validations from respective databases. Prioritised miRNA–mRNA target pairs were integrated into an miRNA–mRNA network based on their correlation and FCs as such generating the OA-specific miRNA interactome (figure 3). The fact that 62 DE miRNAs were interacting with 238 DE target genes reflects that miRNAs are bound to target many genes in a complex structure. As shown in figure 3, the network consists of two large clusters of connected miRNA–mRNA pairs, one in which the miRNAs are downregulated (blue miRNA nodes)

and another in which the miRNAs are upregulated (red miRNA nodes). Notably within the ‘downregulated miRNA cluster’ is the previously unknown OA-related miR-99a-3p that targets 36 DE genes, with 3 of them showing a strong correlation: *FZD1* (r=−0.73, p=0.0001), *ITGB5* (r=−0.70, p=0.00031) and *GDF6* (r=−0.70, p=0.00039) (online supplementary table-S6). Furthermore, these three genes each correlates with at least one other targeting miRNA (figure 3). A notable example in the ‘upregulated miRNA cluster’ is the previously identified miR-143-3 p that targets 16 DE genes. Among these, at least three genes, *DCAKD* (r=−0.71, p=0.0002), *AMIGO1* (r=−0.70, p=0.0003) and *SMAD3* (r=−0.68, p=0.0008), show a strong correlation to miR-143-3 p, which additionally shares target genes with miR-10a-5p and miR-21-5 p, being *TNS3*, *THRA* and *GID8*. Of note in the ‘upregulated miRNA cluster’ is also the miRNA family miR-320, targeting the mRNA of 30 genes including *MANF* and *CISD2*, which are correlated with all miRNAs from this respective family. Besides these two large clusters, there are 15 small clusters, mostly with one miRNA targeting few mRNAs (figure 3). For example, miR-493-3 p forms a separate cluster with its 10 target DE genes. By applying RT-qPCR in n=21 independent preserved OA cartilage samples, we confirmed correlation between the miRNA–mRNA expression for miR-99a-3p with *FZD1* (r=−0.54, p=0.02) and with *GDF6* (r=−0.58, p=0.01) (online supplementary figure-S3).

Functional validation of miRNA–mRNA target pairs

To study the downstream effects of highlighted miRNAs, we studied the effects of miR-143-3 p antagomir and mimic. This miRNA shows singular connections to the *GHR*, *SMAD3*, *AMIGO1* and *DCAKD* genes (figure 4A). As shown in figure 4A, transfection with the miR-143-3 p mimic resulted in consistent downregulation of its singular target genes *AMIGO1* (p=0.071), *SMAD3* (p=0.032), *GHR* (p=0.115) and *DCAKD* (p=0.089). The antagomir of miR-143-3 p did not result in a clear response to the respective target genes. Furthermore, the effects of antagomirs and miR-mimics of miR-99a-3p and miR-329-3 p, both correlating to the *WNT9A*, *FZD1* and *GDF6* genes (figure 4B), were analysed. As shown in figure 4B, the miR-99a and miR-329-3 p mimics and antagomirs resulted in consistent changes in the *WNT9A*, *FZD1* and *GDF6* gene expression; however, the direction of effects was variable. Most notable is the inverse effect of the miR mimics on *GDF6* expression (FC=1.8, p=0.036 and FC=0.6, p=0.059 for miR-329-3 p and miR-99a-3p, respectively). The strongest effect was observed for miR-329-3 p mimic on *WNT9A* expression (FC=0.25, p=0.036). To further explore these interactions, we correlated the expression levels of *WNT9A*, *GDF6* and *FZD1* on transfections with mock controls, antagomirs and mimics of miR-329-3




Figure 3 OA miRNA–mRNA interactome. Network of differentially expressed miRNAs targeting differentially expressed genes between unaffected (preserved) and lesioned OA cartilage. Diamonds are miRNAs and circles genes; edges denote that an miRNA targets the connected gene. The size of the nodes is proportional to the number of edges (interactions). Node colour characterises the strength and the direction of the expression change between unaffected (preserved) and lesioned OA cartilage. Edge thickness corresponds to Pearson's correlation between the miRNA and gene across all samples. miRNA, microRNA; mRNA, messenger RNA; OA, osteoarthritis.

p and miR-99a-3p (online supplementary figure-S4). Notable is the reduced correlation between *WNT9A* and *FZD1* particularly on transfection with, respectively, the miR-329-3 p mimic and the miR-99a-3p antagomir illustrating the different interacting levels at which expression of these genes is controlled by miR-99a-3p and miR-329-3 p.

miRNA-regulated gene pathways

To find specific miRNA-regulated gene pathways involved in OA pathophysiology, we analysed the 238 prioritised mRNAs likely targeted by DE miRNAs in OA cartilage for enrichment in biological processes using the 2387 DE genes as background. As shown in table 2, 10 pathways were significantly enriched, including 'positive regulation of GTPase activity' ($\text{FWER}=9.8 \times 10^{-6}$) and 'nervous system development' ($\text{FWER}=8.4 \times 10^{-5}$). Notable genes involved in the latter were *NLGN1* ($\text{FC}=0.61$, $\text{FDR}=0.014$), which plays a role in synapse function, and *NTF3* ($\text{FC}=2.7$, $\text{FDR}=6.6 \times 10^{-6}$), which controls survival and differentiation of neurons.

DISCUSSION

By integrating overlapping RNA sequencing of mRNA and miRNA in paired preserved and lesioned OA cartilage samples, we presented the first comprehensive, OA-specific, miRNA interactome. Hereto, we identified 142 miRNAs and 2387 genes

with significant DE between lesioned and preserved cartilage. By a strict prioritisation scheme, we created a novel OA-associated miRNA interactome of 62 miRNAs and their 238 likely target mRNAs. Subsequent pathway analyses of the miRNA targeted genes showed significant enrichment for genes that act, among others, within 'positive regulation of GTPase-activity' and 'nervous system development'. To allow biological interpretation of some of the highlighted clusters, functional validation experiments were performed with antagomirs and mimics. We observed that mimics of miR-143-3 p, with singular correlation to the *GHR*, *SMAD3*, *AMIGO1* and *DKAKD* genes, had consistent inverse effects on gene expression. On the other hand, antagomirs and mimics of miR-99a-3p and miR-329-3 p, both paired with *WNT9A*, *FZD1* and *GDF6* genes (figure 4B), had consistent effects on gene expression but with variable directions. Together, our data suggest that interacting levels of miRNAs collectively affect gene expression in the cartilage, yet exemplifies the complexity of functional validation of miRNA–mRNA networks.

Among the enriched miRNA targeted genes in the nervous system development pathway were *NLGN1* and *NTF3*. *NLGN1* encodes neuroligin 1, which is a postsynaptic adhesion molecule involved in the regulation of glutamatergic transmission. More recently it was shown that *NLGN1* is expressed during chondrogenesis and marks cellular identity of articular chondrocytes.²⁷




Figure 4 Functional validation miRNA–mRNA interactions. (A) Expression of *AMIGO1*, *SMAD3*, *GHR* and *DCAKD* in primary chondrocytes transfected with miR-143–3 p mimic or antagomir compared with control as determined by RT-qPCR. (B) Expression of *WNT9A*, *FZD1* and *GDF6* in primary chondrocytes transfected with miR-329–3 p or miR-99a-3p mimic or antagomir compared with control as determined by RT-qPCR. Data shown are the average±SE of the mean for three independent donors (*p<0.05). miRNA, microRNA; mRNA, messenger RNA; RT-qPCR, reverse transcriptase-quantitative PCR.

NTF3 encodes neurotrophin-3, a member of the neurotrophin family that controls survival and differentiation of mammalian neurons. The protein is closely related to both nerve growth factor and brain-derived neurotrophic factor. In our data set we prioritised the *NTF3* gene as a likely target of miR-502–3 p and involved in OA pathophysiology. This since *NTF3* is highly significantly upregulated (FC=2.7, FDR=6.6×10⁻⁶) and miR-502–3 p is significantly downregulated (FC=0.8, FDR=0.04) in lesioned OA cartilage, the expression of *NTF3*

and miR-502–3 p was inversely correlated (r=−0.57, p=0.007), and they are a predicted mRNA–miRNA target pair (miTG score=0.473) (online supplementary table-S6). Targeting such a dysfunctional miRNA–mRNA interaction may represent a therapeutic promise for preclinical development, for example, by applying miRNA mimics of miR-502–3 p. As exemplified by our functional validation, the direct miRNA–mRNA target interaction should, however, be carefully assessed, for example, by luciferase assays. Moreover, we advocate that a systems

Table 2 Pathway analysis of differentially expressed target genes

Term	P values	FWER	Fold enrichment	Genes
Positive regulation of GTPase activity	4.60E-08	9.80E-06	7.68	SNX18, PDGFA, ARHGEF17, S100A10, IRS1, RAB3IP, ELMO1, THY1, FZD10, RGS4, RASA3, ST5, TBC1D20, SRGAP1
Nervous system development	3.93E-07	8.37E-05	7.07	GLRB, NTF3, PCDHB4, NLGN1, NINJ1, EVL, SLC7A5, CSGALNACT1, BZW2, TPP1, DLG3, CRIM1, DCLK1
Protein phosphorylation	5.66E-06	1.20E-03	5.46	RPS6KA5, CCNE1, CCND1, PKN3, WNK4, PHKG2, MKNK2, TESK2, PRKACA, PRKACB, BMPR1B, DCLK1, TRIB2
IRE1-mediated unfolded protein response	6.84E-06	1.46E-03	102.27	TPP1, SRPRB, SEC61A1, ADD1
Stimulatory C-type lectin receptor signalling pathway	6.84E-06	1.46E-03	102.27	RPS6KA5, PSMD1, PRKACA, PRKACB
Extracellular matrix organisation	9.93E-06	2.11E-03	5.16	PDGFA, LUM, ADAMTSL4, TNC, ITGB4, SPINT1, ITGB5, ITGA3, CSGALNACT1, COL9A1, ITGA5, COL27A1, TGFB1
Signal transduction	1.96E-05	4.17E-03	3.06	PTPRK, OSTF1, NTF3, CYTL1, MAPKAPK3, PDE3B, TNFSF13, CDS1, IRS1, SUFU, PLAUR, TMED4, MYD88, EPS8, PKN3, SMOC1, PDE8B, IGFBP1, PRKACB, RASA3, SRGAP1
Tumour necrosis factor-mediated signalling pathway	1.11E-04	2.36E-02	42.61	TNFRSF12A, PSMD1, TNFRSF19, TNFSF13
Activation of protein kinase A activity	1.50E-04	3.19E-02	153.41	PRKAR2B, PRKACA, PRKACB
Cellular response to BMP stimulus	2.18E-04	4.65E-02	34.09	SPINT1, TMEM100, BMPR1B, BMP6

*p<0.05.

BMP, bone morphogenic protein; FWER, familywise error rate.

medicines approach of antagomirs or miR mimics transfections followed by RNA sequencing is preferably taken to obtain a thorough understanding of all biological mechanisms involved. Finally, bioinformatics tools need to be developed that take into account, or take advantage of, the fact that the miRNA 'seed' sequence (nucleotides 2 and 7) can target the 3'UTR region of multiple mRNAs²⁸ or may bind to other parts of the gene.²⁹ Together, our miRNA interactome represents a comprehensive legacy to directly probe miRNAs of interest with their likely downstream signalling pathways, target predictions and/or experimental validations from respective databases. The fact that some of these tools use publication criteria as experimental validation of miRNA–mRNA target pairs should raise awareness that this could confound complex miRNA–mRNA target interactions rather than illuminating them.

Within the interactome, miR-99a-3p, not previously associated with OA, targets the highest number of genes (n=36), with 20 of those genes targeted only by miR-99a-3p, while 16 genes were also targeted by other DE miRNAs. Of the latter, *GDF6* is targeted by three other miRNAs (miR-329-3 p, miR-339-5 p, miR-532-3 p), with miR329-3p having the strongest inverse correlation ($r=-0.67$). *GDF6* is a member of the transforming growth factor-beta super family whose members are essential for normal formation of the bones and joints in the limbs, skull and axial skeleton.³⁰ Also notable is that *GDF6* is an important paralogue of *GDF5*, the most consistently OA susceptibility gene found to date.³¹ Moreover, *GDF5* has recently been identified as one of the key genes able to stratify two OA subgroups of knee articular cartilage based on expression levels.³²

In our DE miRNA data set, we identified many of the previously reported, OA-associated, miRNAs such as miR-206²² and miR-140.^{15 16} However, in our miRNA interactome, these miRNAs did not necessarily correlate to their previously reported target genes. For example, miR-140-5 p in our miRNA interactome is only connected to *RGS4* (figure 3) and not to *ADAMTSS5*, *MMP13* and *IGFBP5*, as reported previously by Tardif *et al.*^{15 16} To explore this further, we report in online supplementary table-S7 our miRNA and mRNA expression data of the most consistently reported miRNA–mRNA target pairs, for example, as reported in a recent review.³³ As shown in online supplementary table-S7, miR-140-5 p has only very modest correlations to these previous reported target genes, likely reflecting their indirect effects. Moreover, some of the previously reported miRNAs are not among the ones presented in the miRNA interactome due to our strict prioritisation approach (figure 3). For example, miR-27a-3p is highly upregulated in lesioned OA cartilage ($FC=1.8$, $FDR=5.0 \times 10^{-4}$), but is not present in our miRNA interactome because it has significant positive correlation to *MMP13* ($r=0.5$, $p=3.6 \times 10^{-2}$), and this gene does not show significant DE in preserved versus lesioned OA cartilage ($FC=0.9$, $FDR=8.34 \times 10^{-1}$).

Another example of earlier reported miRNA associated to OA pathophysiology is miR-206. In a recent study, it was shown that increased expression of miR-206 significantly inhibited proliferation of chondrocytes while promoting expression of catabolic enzymes and apoptosis-inducing factors, suggesting that inhibition of miR-206 may control cartilage degradation in OA.²² In our data set miR-206 indeed exhibits a high and significant upregulation in lesioned compared with preserved OA cartilage ($FC=4.9$, $FDR=2.6 \times 10^{-6}$) and, based on the here identified interactions with *CFH*, *IFIH1*, *NINJ1*, *GPM6A*, *L3MBTL4*, *COLEC12*, *PLCD3*, *ACSF2*, *CYTL1*, *RHNO1*, *FIBIN* and *C22orf39*, we advocate that these genes may be involved in this process (figure 3). Taken together, the field of miRNA biology

has demonstrated that miRNAs are bound to target multiple mRNAs in a network and, via dysregulation, causal to complex diseases,³⁴ including OA.³⁵ Moreover, targeting dysfunctional miRNA–mRNA interactions has emerged as an important therapeutic promise for preclinical development. As such, the here identified miRNA interactome of OA articular cartilage may represent a first important step to fulfil this promise. Nevertheless, our functional validation experiments highlighted that additional high-throughput (ie, high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP)) functional analyses towards systems medicines approaches are necessary to demonstrate direct binding of miRNAs to specific target genes and concurrent downstream changes in all mRNA expression levels.

Author affiliations

¹Department of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

²The Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands

³Leiden Computational Biology Center, Leiden University Medical Center, Leiden, The Netherlands

⁴Sequence Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands

⁵Department of Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands

Acknowledgements We thank all study participants of the RAAK study. The Leiden University Medical Center has and is supporting the RAAK study. We thank Elwin Verheijen for mRNA and miRNA isolations.

Contributors All authors have made substantial contributions to the completion of this study. Study concept and design: RCdA, YFMR, AM, MR, IM. Data analyses: RCdA, YFMR, AM, HM, SMK. Acquisition of material and data: RCdA, WdH, NL, MvH, EH, HEDS, ARR, PES, RGHNN, IM, YFMR. Preparation of the manuscript: RCdA, YFMR, AM, MR, IM. Critical reviewing and approval of the manuscript: all authors.

Funding The study was funded by the Foundation for Research in Rheumatology (FOREUM), Dutch Arthritis Society (DAA_10_1-402), BBMRI-NL Complementation project (CP2013-83), Ana Fonds (O2015-27), and Dutch Scientific Research Council NWO /ZonMW VICI scheme (nr 91816631/528).

Competing interests None declared.

Patient consent for publication Obtained.

Ethics approval Cohorts ethical approval for the RAAK study (Ramos *et al*, *PLoS One* 2014) was obtained from the medical ethics committee of the LUMC (P08.239).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data from the study are available by public access within the text or online.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0>

REFERENCES

- 1 Woolf AD, Erwin J, March L. The need to address the burden of musculoskeletal conditions. *Best Pract Res Clin Rheumatol* 2012;26:183–224.
- 2 Xu Y, Barter MJ, Swan DC, *et al*. Identification of the pathogenic pathways in osteoarthritic hip cartilage: commonality and discord between hip and knee OA. *Osteoarthritis Cartilage* 2012;20:1029–38.
- 3 den Hollander W, Ramos YF, Bomer N, *et al*. Transcriptional associations of osteoarthritis-mediated loss of epigenetic control in articular cartilage. *Arthritis Rheumatol* 2015;67:2108–16.
- 4 Ramos YF, den Hollander W, Bovée JV, *et al*. Genes involved in the osteoarthritis process identified through genome wide expression analysis in articular cartilage; the RAAK study. *PLoS One* 2014;9:e103056.
- 5 Zhang L, Yang M, Marks P, *et al*. Serum non-coding RNAs as biomarkers for osteoarthritis progression after ACL injury. *Osteoarthritis Cartilage* 2012;20:1631–7.
- 6 Lotz MK, Caramés B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. *Nat Rev Rheumatol* 2011;7:579–87.
- 7 Meulenbelt I. Osteoarthritis year 2011 in review: genetics. *Osteoarthritis Cartilage* 2012;20:218–22.

- 8 O'Connor CJ, Case N, Guilak F. Mechanical regulation of chondrogenesis. *Stem Cell Res Ther* 2013;4:61.
- 9 Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 2003;33 Suppl:245–54.
- 10 Sliker RC, Bos SD, Goeman JJ, et al. Identification and systematic annotation of tissue-specific differentially methylated regions using the Illumina 450k array. *Epigenetics Chromatin* 2013;6:26.
- 11 Laurent L, Wong E, Li G, et al. Dynamic changes in the human methylome during differentiation. *Genome Res* 2010;20:320–31.
- 12 Ramos YF, Meulenbelt I. The role of epigenetics in osteoarthritis: current perspective. *Curr Opin Rheumatol* 2017;29:119–29.
- 13 Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov* 2017;16:203–22.
- 14 Vicente R, Noël D, Pers YM, et al. Deregulation and therapeutic potential of microRNAs in arthritic diseases. *Nat Rev Rheumatol* 2016;12:496.
- 15 Tardif G, Pelletier JP, Fahmi H, et al. NFAT3 and TGF- β /SMAD3 regulate the expression of miR-140 in osteoarthritis. *Arthritis Res Ther* 2013;15:R197.
- 16 Tardif G, Hum D, Pelletier J-P, et al. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. *BMC Musculoskelet Disord* 2009;10:1–11.
- 17 Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 2015;4.
- 18 Paraskevopoulou MD, Georgakilas G, Kostoulas N, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. *Nucleic Acids Res* 2013;41:W169–W173.
- 19 Chou CH, Chang NW, Shrestha S, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. *Nucleic Acids Res* 2016;44(D1):D239–D247.
- 20 Vlachos IS, Paraskevopoulou MD, Karagkouni D, et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. *Nucleic Acids Res* 2015;43:D153–D159.
- 21 Jiao X, Sherman BT, Huang daW, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. *Bioinformatics* 2012;28:1805–6.
- 22 Ni Z, Shang X, Tang G, et al. Expression of miR-206 in Human Knee Articular Chondrocytes and Effects of miR-206 on Proliferation and Apoptosis of Articular Chondrocytes. *Am J Med Sci* 2018;355:240–6.
- 23 Matsukawa T, Sakai T, Yonezawa T, et al. MicroRNA-125b regulates the expression of aggrecanase-1 (ADAMTS-4) in human osteoarthritic chondrocytes. *Arthritis Res Ther* 2013;15:R28–11.
- 24 Liang ZJ, Zhuang H, Wang GX, et al. MiRNA-140 is a negative feedback regulator of MMP-13 in IL-1 β -stimulated human articular chondrocyte C28/I2 cells. *Inflamm Res* 2012;61:503–9.
- 25 Haseeb A, Makki MS, Khan NM, et al. Deep sequencing and analyses of miRNAs, isomiRs and miRNA induced silencing complex (miRISC)-associated miRNome in primary human chondrocytes. *Sci Rep* 2017;7:15178.
- 26 Ramos YF, Bos SD, van der Breggen R, et al. A gain of function mutation in TNFRSF11B encoding osteoprotegerin causes osteoarthritis with chondrocalcinosis. *Ann Rheum Dis* 2015;74:1756–62.
- 27 Ferguson GB, Van Handel B, Bay M, et al. Mapping molecular landmarks of human skeletal ontogeny and pluripotent stem cell-derived articular chondrocytes. *Nat Commun* 2018;9:3634.
- 28 Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. *PLoS Biol* 2005;3:e85.
- 29 Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions--beyond repression of gene expression. *Nat Rev Genet* 2014;15:599–612.
- 30 Settle SH, Rountree RB, Sinha A, et al. Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse Gdf6 and Gdf5 genes. *Dev Biol* 2003;254:116–30.
- 31 Reynard LN, Loughlin J. The genetics and functional analysis of primary osteoarthritis susceptibility. *Expert Rev Mol Med* 2013;15:e2.
- 32 Soul J, Dunn SL, Anand S, et al. Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage. *Ann Rheum Dis* 2018;77:423.
- 33 Sondag GR, Haqqi TM. The Role of MicroRNAs and Their Targets in Osteoarthritis. *Curr Rheumatol Rep* 2016;18:56.
- 34 Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. *Nat Rev Genet* 2016;17:719–32.
- 35 Ntoumou E, Tzetzis M, Braoudaki M, et al. Serum microRNA array analysis identifies miR-140-3p, miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic processes. *Clin Epigenetics* 2017;9:1–15.